TickerTalks
Browse all tickers →
TickerTalks›$SLBT
SLSLBT

SL Science Holding Ltd

$SLBT·$21M·Biotechnology·Healthcare
$1.60-5.9%1Y-79.5%
Price updated 16h ago·X counts updated 30d ago
SLSLBT
$SLBTSL Science Holding Ltd
$1.60-5.88%1 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $SLBT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

1X posts · last 7 days
No mention history yet
Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-06-24

SLBT is referenced as a low-float runner archetype, with traders citing it as a comparison point for other small-float Israeli and microcap names like WXM, INHD, EHGO, and NXTS. The mentions are retrospective, framing SLBT's prior squeeze move as the template others are trying to repeat. Tone around the SLBT precedent is positive momentum-oriented.

Read what X is saying about $SLBT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $SLBT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

SLBT is a $21M low-float Israeli micro-cap being referenced as a prior-squeeze template.

SL Science Holding Ltd (SLBT) is a $21M healthcare micro-cap. The business is pre-revenue at scale and the stock is being referenced as a template for other low-float runners.

  • The business is pre-scale: operating margin -36%, ROIC -20%, PS 20.9x — standard micro-cap biotech / health profile where the P&L is uninformative on the thesis.
  • 52-week range position is unavailable, vol multiplier 0.47 — thinly-traded with no clear directional-event trigger from the chart.
  • The retail signal is specific but retrospective: SLBT is cited as the comparison point for other low-float squeeze setups (WXM, INHD, EHGO, NXTS) — the move already happened, and the current chatter is template-reference rather than actionable.

Absent a scheduled earnings date, this trades on announcements and float dynamics. Any specific operational disclosure extends the stock. A dilutive raise or float registration is the clear near-term risk.

Agrees with X sentimentThe thread has substantive drivers but retrospective — SLBT referenced as low-float runner template for other small-float Israeli / micro-cap names (WXM, INHD, EHGO, NXTS) — the squeeze move already occurred, so the signal is template-reference rather than live positioning.

What to watch: Any operational disclosure, float / registration filings, operating cash balance, and dilution-watch filings. A dilutive raise is the clear invalidator.

thin bundle

Read the AI verdict on $SLBT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Blank check company (SPAC) formed to identify and complete a strategic business combination with one or more target companies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SLBT.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $SLBT

Neutral — Horizon Space Acquisition II Corp; exposure to the industry macro driver is limited or indirect.

Top industry ETF

$IBBiShares Biotechnology ETF
+21.4%YTD
+38.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
0.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-20.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-35.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
20.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-25.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
57.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-46.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 226.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuySep 29Ching-dong WangCEO4.5M sh$2.3M

See when $SLBT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentOct 1SC 13D/A
SC 13DActivist position (5%+)Jun 18SC 13D
AI summary

Ching-Dong Wang (Taipei, Taiwan) filed an initial Schedule 13D for SL Science Holding Ltd (SLBT) as of June 12, 2026, representing new controlling-owner and director disclosure. Wang appears to be the company's controlling founder given the dominant ~333M share stake disclosed in the accompanying Form 3. New controlling-holder 13D for SLBT — Wang's 5%+ disclosure initiates the required Schedule 13D reporting as the company's founding and controlling shareholder.

3New insider — initial holdingsJun 183
AI summary

Ching-Dong Wang filed an initial Form 3 for SL Science Holding Ltd (SLBT), reporting 333,832,129 ordinary shares including 329,286,823 held by SL Link Holdings and additional direct shares. This represents controlling ownership — Ching-Dong Wang effectively controls SLBT through SL Link Holdings, with a dominant ~333.8M share position that gives him decisive influence over the company.

3New insider — initial holdingsJun 173
AI summary

Qian Xu filed an initial Form 3 for SL Science Holding Ltd, reporting 20,000 directly-owned ordinary shares as of June 17, 2026. Routine initial insider disclosure — small equity position.

3New insider — initial holdingsJun 163
AI summary

Johnson Lau filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

3New insider — initial holdingsJun 163
AI summary

Ethan Shen filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

3New insider — initial holdingsJun 163
AI summary

Mingche Liu filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

3New insider — initial holdingsJun 163
AI summary

Kwo-Liang Chen filed an initial Form 3 for SL Science Holding Ltd with no securities beneficially owned. Routine initial director disclosure for SLBT at listing — no equity position.

+ 13 other (5 6-Ks · 3 3s · 1 EFFECT · 1 F-1) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastomaglobenewswire.com·8d agoSL Science: A $1.15 Billion Valuation Built On Preclinical Promisesseekingalpha.com·16d agoSL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Companyglobenewswire.com·30d agoSL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platformglobenewswire.com·36d agoSL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastomaglobenewswire.com·52d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$NKTR
Voices on X · last 7 days

No standout posts about $SLBT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport